International Journal For Multidisciplinary Research

E-ISSN: 2582-2160   •   Impact Factor: 9.24

A Widely Indexed Open Access Peer Reviewed Multidisciplinary Bi-monthly Scholarly International Journal

Call for Paper Volume 8, Issue 1 (January-February 2026) Submit your research before last 3 days of February to publish your research paper in the issue of January-February.
Submit Research Paper Join as a Reviewer

Plagiarism is checked by the leading plagiarism checker TurnItIn

Call for Paper

Volume 8 Issue 1
January-February 2026

Submit your research paper

Indexing Partners
Academia Advanced Sciences Index Bielefeld Academic Search Engine CiteSeer DRJI Google Scholar Independent Search Engine & Directory Network ISI (International Scientific Indexing) Issuu Mendeley Research Networks
RefSeek ResearcherId - Thomson Reuters ResearchGate Scirus Scribd Semantic Scholar UTeM - Universiti Teknikal Malaysia Melaka Wiki for Call for Papers WorldCat Zenodo

Scientific Validation of Vidangadi Guggulu in Diabetes Mellitus using Streptozotocin-induced Wistar Rat Model

Author(s) Dr. Nisha, Dr. Pratap Kumar Kumar Sahu, Dr. Shakti Ketan Prusty, Dr. Chandan Kumar Sahoo
Country India
Abstract Diabetes mellitus is a chronic metabolic disorder characterized by persistent hyperglycaemia and associated complications. In Ayurveda, diabetes is correlated with Prameha, and Vidangadi Guggulu is traditionally indicated for Meha as per classical texts (Chakradatta, 44/69-70).[10] Despite its traditional use, experimental validation is limited.
The present study evaluated the antihyperglycaemic activity of Vidangadi Guggulu in streptozotocin (STZ)-induced diabetic Wistar rats. Twenty-four healthy adult Wistar albino male rats were divided into four groups (n = 6): normal control, diabetic control, standard drug treated (Metformin 100 mg/kg, p.o.), and test drug treated (Vidangadi Guggulu 50 mg/kg, p.o.). Diabetes was induced by a single intraperitoneal injection of STZ (40 mg/kg). Fasting blood glucose (FBG) was measured at baseline, after STZ induction, and after 14 days of treatment.
STZ administration caused significant hyperglycaemia in all diabetic groups. Treatment with Vidangadi Guggulu significantly reduced FBG levels (63.98%), comparable to Metformin (69.41%) (p < 0.001).
These results suggest that Vidangadi Guggulu, as described in Chakradatta (44/69-70), possesses significant antihyperglycaemic activity, supporting its traditional use in the management of Prameha. Further studies are needed to confirm its therapeutic potential in humans.
Keywords Vidangadi Guggulu, Meha, Prameha, Diabetes mellitus, Streptozotocin, Antihyperglycaemic activity, Antidiabetic activity
Field Medical / Pharmacy
Published In Volume 8, Issue 1, January-February 2026
Published On 2026-01-30
DOI https://doi.org/10.36948/ijfmr.2026.v08i01.67644
View / Download PDF File

Share this



E-ISSN 2582-2160
CrossRef

CrossRef DOI is assigned to each research paper published in our journal.

IJFMR DOI prefix is
10.36948/ijfmr

Downloads
Research Paper Format Copyright Permission Form and Undertaking Form Cover Page Vol 8 Isu 1Cover Page Vol 7 Isu 6Cover Page Vol 7 Isu 5

All research papers published on this website are licensed under Creative Commons Attribution-ShareAlike 4.0 International License, and all rights belong to their respective authors/researchers.

CC-BY-SA Open Access

About IJFMR
Fees & Payment
Current Issue
Publication Archive 		Submit Research Paper
Track Submission Status
Publication Guidelines
Publication Ethics
Peer Review & Plagiarism 		Join as a Reviewer
Editors & Reviewers
Reviewer Referral Program
Get Reviewer Membership Certi. 		Website/Journal Policies
Usage Policy
Content Policies
Privacy Policy
Contact Us +91-9687-828-838 editor@ijfmr.com